ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 133 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q1 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $246 | -10.5% | 9,646 | +0.8% | 0.00% | – |
| Q2 2023 | $275 | -25.1% | 9,574 | -37.4% | 0.00% | – |
| Q1 2023 | $367 | +41.7% | 15,300 | 0.0% | 0.00% | – |
| Q4 2022 | $259 | -99.9% | 15,300 | -0.1% | 0.00% | – |
| Q3 2022 | $227,000 | -5.4% | 15,309 | +0.3% | 0.00% | – |
| Q2 2022 | $240,000 | -41.7% | 15,260 | -0.1% | 0.00% | – |
| Q1 2022 | $412,000 | -27.1% | 15,274 | -0.0% | 0.00% | -100.0% |
| Q4 2021 | $565,000 | -22.8% | 15,279 | -0.2% | 0.00% | 0.0% |
| Q3 2021 | $732,000 | +21.0% | 15,314 | -14.3% | 0.00% | 0.0% |
| Q2 2021 | $605,000 | -22.0% | 17,868 | -5.0% | 0.00% | 0.0% |
| Q1 2021 | $776,000 | -10.1% | 18,800 | -5.5% | 0.00% | 0.0% |
| Q4 2020 | $863,000 | +67.6% | 19,900 | +65.8% | 0.00% | 0.0% |
| Q3 2020 | $515,000 | -8.2% | 12,000 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $561,000 | – | 12,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SEVEN EIGHT CAPITAL, LP | 46,819 | $2,031,000 | 0.47% |
| Orbimed Advisors | 1,206,886 | $49,844,000 | 0.47% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 25,000 | $1,033,000 | 0.40% |
| ARK Investment Management | 3,331,889 | $137,607,000 | 0.27% |
| FEDERATED HERMES, INC. | 3,203,000 | $132,284,000 | 0.26% |
| MGO ONE SEVEN LLC | 26,990 | $1,114,000 | 0.19% |
| Koss-Olinger Consulting, LLC | 20,000 | $826,000 | 0.14% |
| Jump Financial, LLC | 35,400 | $1,462,000 | 0.14% |
| Graham Capital Management, L.P. | 74,262 | $3,067,000 | 0.14% |
| New England Research & Management, Inc. | 6,005 | $248,000 | 0.14% |